Biogen Inc  

(Public, NASDAQ:BIIB)   Watch this stock  
Find more results for biib
403.94
+7.73 (1.95%)
After Hours: 403.94 0.00 (0.00%)
Jun 30, 5:12PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 396.66 - 405.00
52 week 290.85 - 480.18
Open 403.55
Vol / Avg. 1.58M/1.22M
Mkt cap 93.67B
P/E 29.16
Div/yield     -
EPS 13.85
Shares 235.23M
Beta 0.99
Inst. own 92%
Jul 21, 2015
Q2 2015 Biogen Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jun 12, 2015
Biogen Idec Inc Annual Shareholders Meeting (Estimated)
Jun 10, 2015
Biogen Inc Annual Shareholders Meeting - Webcast
May 27, 2015
Biogen Inc at Sanford C Bernstein Strategic Decisions Conference
May 19, 2015
Biogen Inc at UBS Global Healthcare Conference
May 13, 2015
Biogen Inc at Bank of America Merrill Lynch Health Care Conference
May 6, 2015
Biogen Inc at Deutsche Bank Health Care Conference
Apr 24, 2015
Q1 2015 Biogen Idec Inc Earnings Release
Apr 24, 2015
Q1 2015 Biogen Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin 32.13% 30.47%
Operating margin 43.75% 40.94%
EBITD margin - 47.46%
Return on average assets 22.30% 22.59%
Return on average equity 29.36% 30.21%
Employees 7,550 -
CDP Score - 81 C

Address

225 Binney St
CAMBRIDGE, MA 02142-1031
United States - Map
+1-781-4642000 (Phone)
+1-302-6365454 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha
About Company - Wikipedia

Description

Biogen Inc., formerly Biogen Idec Inc., is a global biopharmaceutical company. The Company is focused on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. The Company develops, manufactures and markets products designed for the treatment of multiple sclerosis (MS) and hemophilia A and B. The Company's marketed products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, FAMPYRA for multiple sclerosis (MS), ALPROLIX for hemophilia B, and ELOCTATE for hemophilia A, among others. It also collaborates on the development and commercialization of RITUXAN (rituximab), which is a monoclonal antibody for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA, which is for the treatment of chronic lymphocytic leukemia.

Officers and directors

Stelios B. Papadopoulos Ph.D. Independent Chairman of the Board
Age: 71
Bio & Compensation  - Reuters
George A. Scangos Ph.D. Chief Executive Officer, Director
Age: 67
Bio & Compensation  - Reuters
Paul J. Clancy Chief Financial Officer, Executive Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Kenneth A. Di Pietro Executive Vice President - Human Resources
Age: 56
Bio & Compensation  - Reuters
Susan H. Alexander Esq. Executive Vice President, Chief Legal Officer and Corporate Secretary
Age: 58
Bio & Compensation  - Reuters
John G. Cox Executive Vice President - Pharmaceutical Operations and Technology
Age: 52
Bio & Compensation  - Reuters
Steven H. Holtzman Executive Vice President - Corporate Development
Age: 60
Bio & Compensation  - Reuters
Adriana Karaboutis Executive Vice President - Technology and Business Solutions
Age: 52
Bio & Compensation  - Reuters
Tony Kingsley Executive Vice President - Global Commercial Operations
Age: 51
Bio & Compensation  - Reuters
Douglas E. Williams Ph.D. Executive Vice President - Research and Development
Age: 57
Bio & Compensation  - Reuters